bexarotene has been researched along with cytarabine in 6 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (16.67) | 29.6817 |
| 2010's | 4 (66.67) | 24.3611 |
| 2020's | 1 (16.67) | 2.80 |
| Authors | Studies |
|---|---|
| Benfenati, E; Raska, I; Toropov, AA; Toropova, AP | 1 |
| Afshari, CA; Chen, Y; Dunn, RT; Hamadeh, HK; Kalanzi, J; Kalyanaraman, N; Morgan, RE; van Staden, CJ | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Acebo, E; Díaz-Pérez, JL; García-Ruiz, JC; Izu, R; Martínez de Lagrán, Z; Pérez-Barrio, S | 1 |
| Acebo-Mariñas, E; Aperribay-Esparza, A; de Quintana-Sancho, A; Gardeazabal-García, J | 1 |
| Gong, P; Huan, H; Liu, Z; Lu, Z; Wang, M; Wang, W; Wu, B; Yang, C | 1 |
1 review(s) available for bexarotene and cytarabine
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
5 other study(ies) available for bexarotene and cytarabine
| Article | Year |
|---|---|
QSPR modeling of octanol/water partition coefficient of antineoplastic agents by balance of correlations.
Topics: Antineoplastic Agents; Models, Chemical; Octanols; Quantitative Structure-Activity Relationship; Water | 2010 |
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Transport; Chemical and Drug Induced Liver Injury; Cluster Analysis; Drug-Related Side Effects and Adverse Reactions; Humans; Liver; Male; Multidrug Resistance-Associated Proteins; Pharmacokinetics; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Risk Assessment; Risk Factors; Toxicity Tests | 2013 |
[Autologous hematopoietic stem cell transplantation followed by oral bexarotene in a patient with advanced mycosis fungoides].
Topics: Adolescent; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bexarotene; Busulfan; Cisplatin; Combined Modality Therapy; Cyclophosphamide; Cytarabine; Doxorubicin; Etoposide; Female; Humans; Interferon alpha-2; Interferon-alpha; Mechlorethamine; Methylprednisolone; Mycosis Fungoides; Peripheral Blood Stem Cell Transplantation; Prednisone; PUVA Therapy; Recombinant Proteins; Remission Induction; Tetrahydronaphthalenes; Transplantation, Autologous; Vincristine | 2008 |
Cerebral involvement as the first extracutaneous manifestation of mycosis fungoides.
Topics: Adrenal Cortex Hormones; Antineoplastic Combined Chemotherapy Protocols; Bexarotene; Brain; Carmustine; Combined Modality Therapy; Cytarabine; Disease Progression; Fatal Outcome; Female; Humans; Lymphoma, Large-Cell, Anaplastic; Memory Disorders; Methotrexate; Middle Aged; Mycosis Fungoides; Nystagmus, Pathologic; PUVA Therapy; Skin Neoplasms; Tetrahydronaphthalenes | 2015 |
The cuproptosis-related signature associated with the tumor environment and prognosis of patients with glioma.
Topics: Apoptosis; Bexarotene; Bortezomib; Brain Neoplasms; Class I Phosphatidylinositol 3-Kinases; Copper; Cytarabine; DNA-Binding Proteins; ErbB Receptors; Gene Expression Regulation, Neoplastic; Glioma; Humans; Prognosis; RNA-Binding Proteins; Tumor Microenvironment | 2022 |